NCT06409663View on ClinicalTrials.gov

A Strain Change Study for SARS-CoV-2 rS Vaccines

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

October 15, 2024

Study Completion Date

April 17, 2025

Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Interventions
BIOLOGICAL

NVX-CoV2705 Vaccine

All injections will be administered in a 0.5 mL injection volume at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant at each injection.

Trial Locations (2)

78705

Benchmark Research, Austin

85044

Foothills Research Center - CCT Research, Phoenix

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY

NCT06409663 - A Strain Change Study for SARS-CoV-2 rS Vaccines | Biotech Hunter | Biotech Hunter